诱导化疗后白蛋白结合型紫杉醇、卡培他滨与放疗治疗局部晚期和交界可切除胰腺癌:Ⅰ期试验及基于影像的生物标志物验证
这项Ⅰ期试验在局部晚期和交界可切除胰腺癌患者中,评估诱导化疗后白蛋白结合型紫杉醇联合卡培他滨与放疗的安全性及疗效,并评价基于CT的肿瘤界面反应生物标志物。白蛋白结合型紫杉醇最大耐受剂量为75 mg/m2,中位总生存期21.2个月、无进展生存期8.1个月,界面反应Ⅰ型与更好的总生存(P = .004)和无进展生存(P = .03)相关。
要点
- 白蛋白结合型紫杉醇在巩固放化疗方案中的最大耐受剂量为75 mg/m2。
- 23例患者中7例接受手术切除,中位总生存期21.2个月、无进展生存期8.1个月。
- 界面反应Ⅰ型与更好的总生存(P = .004)和无进展生存(P = .03)相关。
核心结论
- 确定了白蛋白结合型紫杉醇在胰腺导管腺癌巩固放化疗方案中的最大耐受剂量。
- 初步疗效结果值得开展Ⅱ期试验评估。
- 界面反应可能用于个体化治疗。
研究设计与样本
- Ⅰ期试验,采用标准3+3设计,白蛋白结合型紫杉醇设50、75和100 mg/m2三个递增剂量水平,联合卡培他滨和放疗。
- 纳入病理确诊胰腺导管腺癌、经CT诊断为局部晚期或交界可切除、并接受诱导化疗的患者,共23例(局部晚期14例,交界可切除9例)。
主要发现
- 剂量水平1(n = 3)和水平2(n = 3)初始组未报告3级和4级毒性。
- 剂量水平3初始组2例出现剂量限制性毒性,确定水平2为最大耐受剂量。
- 水平2组扩展额外15例(试验总计23例),其中5例出现3级毒性。
- 7例患者接受手术切除。
- 中位总生存期和无进展生存期分别为21.2个月和8.1个月。
关键数值与推荐
- 剂量限制性毒性定义为3级或以上毒性。
- 白蛋白结合型紫杉醇最大耐受剂量为75 mg/m2。
- 放化疗完成后4至6周重新分期,稳定或缓解者接受手术切除。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出初步疗效结果值得开展Ⅱ期试验评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Effective consolidative chemoradiation (CRT) regimens are lacking. In this phase 1 trial, we evaluated the safety and efficacy of nab-paclitaxel, capecitabine, and radiation therapy after induction chemotherapy in patients with locally advanced and borderline-resectable pancreatic cancer (LAPC and BRPC). Also, we evaluated a computed tomography (CT)-based biomarker of response. METHODS AND MATERIALS: Eligible patients had pathologically confirmed pancreatic ductal adenocarcinoma, underwent computed tomography-imaging, received a diagnosis of LAPC or BRPC, and received induction chemotherapy. Standard 3 + 3 study design was used, with 3 escalating nab-paclitaxel dose levels (50, 75, and 100 mg/m2) with concurrent capecitabine and RT in cohort sizes of 3 starting at the lowest dose. Dose limiting toxicity was defined as grade 3 or higher toxicity. Patients were restaged 4 to 6 weeks post-CRT completion, and surgical resection was offered to those with stable/responsive disease. We scored the tumor interface response (IR) postchemotherapy and post-CRT into type I (remained/became more defined) and type II (became less defined). Overall survival (OS) and progression-free survival (PFS) from time of CRT were estimated using Kaplan-Meier method. P ≤ .05 was considered significant. RESULTS: Twenty-three patients started and finished on protocol (LAPC = 14, BRPC = 9). No grade 3 and 4 toxicities were reported in level 1 (n = 3) or level 2 (n = 3) initial groups. Two patients in the initial level 3 group developed dose limiting toxicity, establishing level 2 dose as the maximal tolerated dose. Level 2 group was expanded for additional 15 patients (for a total of 23 on trial), 5 of whom developed grade 3 toxicities. Seven patients underwent surgical resection. Median OS and PFS were 21.2 and 8.1 months, respectively. Type I IR was associated with better OS (P = .004) and PFS (P = .03) compared with type II IR. CONCLUSIONS: We established the maximum tolerated dose for nab-paclitaxel in a consolidative CRT regimen for pancreatic ductal adenocarcinoma. Preliminary efficacy results warrant phase 2 trial evaluation. IR may be used for personalized treatment.
引用
- Koay EJ, Zaid M, Aliru M, et al. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022. PMID: 35863672. doi:10.1016/j.ijrobp.2022.06.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。